Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
0.7897
-0.0319 (-3.88%)
May 6, 2025, 4:00 PM EDT - Market closed
Prelude Therapeutics Employees
Prelude Therapeutics had 131 employees as of December 31, 2024. The number of employees increased by 3 or 2.34% compared to the previous year.
Employees
131
Change (1Y)
3
Growth (1Y)
2.34%
Revenue / Employee
$53,435
Profits / Employee
-$970,786
Market Cap
44.58M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 131 | 3 | 2.34% |
Dec 31, 2023 | 128 | 6 | 4.92% |
Dec 31, 2022 | 122 | 6 | 5.17% |
Dec 31, 2021 | 116 | 48 | 70.59% |
Dec 31, 2020 | 68 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
Eli Lilly and Company | 47,000 |
PRLD News
- 4 hours ago - Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 days ago - Prelude Therapeutics to Participate in Citizens Life Sciences Conference - GlobeNewsWire
- 11 days ago - Prelude Announces Presentations at 2025 AACR Annual Meeting - GlobeNewsWire
- 2 months ago - Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 - GlobeNewsWire
- 2 months ago - Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies - GlobeNewsWire
- 5 months ago - Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - GlobeNewsWire
- 6 months ago - Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium - GlobeNewsWire